Vitamin K2 Researcher Ranks Among Top Scientists Worldwide

OSLO, NorwayResearchGate recognized vitamin K2 researcher Cees Vermeer for ranking among the top 2.5 percent of worldwide scientists.

Vermeer, professor of the Cardiovascular Research Institute Maastricht and CEO of VitaK BV, recently led a research team that studied vitamin K2 menaquinone-7 for three years, which has shown the most significant bone health finding in recent history. Vitamin K2, taken daily and long-term, can prevent bone loss and porosity in womeneven after menopause.

Vermeer has been lauded for his pioneering work in elucidating vitamin K and vitamin K2, its structure, its nature and its benefits in human health. His team's study was recently published in Osteoporosis International. The study represents part of a long-term collaboration program between NattoPharma ASA and VitaK.

NattoPharma CEO Hogne Vik said Vermeer's prestigious distinction supports the company's campaign to fight vitamin K2 deficiency.   

 The R&D agreement with VitaK and University of Maastricht, along with other outstanding medical institutions, secures explorative and clinical results for NattoPharmas present and future use of MenaQ7," Vik said. "We will continue to stimulate further research of vitamin K2 in both biochemical and clinical settings." 

NattoPharma gained its U.S. patent for vitamin K2 in March 2013.